CAS 1059734-66-5
:BMS-833923
Description:
BMS-833923 is a small molecule inhibitor primarily developed for its potential therapeutic applications in oncology, particularly targeting the protein kinase B (AKT) pathway, which is crucial in regulating cell growth and survival. This compound exhibits selective inhibition of AKT, thereby interfering with cancer cell proliferation and survival mechanisms. BMS-833923 is characterized by its ability to induce apoptosis in cancer cells and has been studied in various preclinical and clinical settings. Its chemical structure includes specific functional groups that contribute to its binding affinity and selectivity for the target kinase. The compound has undergone various phases of clinical trials to evaluate its efficacy and safety profile in patients with specific types of cancer. As with many investigational drugs, the pharmacokinetics, metabolism, and potential side effects are critical areas of study to determine its therapeutic viability. Overall, BMS-833923 represents a promising avenue in targeted cancer therapy, reflecting the ongoing efforts to develop more effective and selective treatment options for malignancies.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.
N-(2-Methyl-5-((Methylamino)Methyl)Phenyl)-4-((4-Phenylquinazolin-2-Yl)Amino)Benzamide
CAS:N-(2-Methyl-5-((Methylamino)Methyl)Phenyl)-4-((4-Phenylquinazolin-2-Yl)Amino)BenzamidePurity:98%Molecular weight:473.57g/molBMS-833923
CAS:<p>BMS-833923 (XL-139), an orally bioavailable Smoothened antagonist, inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner (IC50: 21 nM).</p>Formula:C30H27N5OPurity:99.47% - 99.76%Color and Shape:SolidMolecular weight:473.57BMS 833923
CAS:Controlled Product<p>Applications BMS 833923 is an antagonist of smoothened, a key hedgehog (Hh) pathway regulator.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Brechbiel, J., et. al.: Cancer Treat. Rev., 40, 750 (2014); Cortes, J., et. al.: J. Natl. Compr. Cancer Netw., 11, 10 (2013)<br></p>Formula:C30H27N5OColor and Shape:NeatMolecular weight:473.57BMS-833923
CAS:<p>BMS-833923 is a small molecule that inhibits the activity of epidermal growth factor receptor (EGFR) tyrosine kinase in hypoxic tumor cells, which are found in approximately one-third of all solid tumors. BMS-833923 has been shown to inhibit EGFR tyrosine kinase activity by binding to the ATP site of EGFR and blocking the formation of ATP-EGFR complexes. The inhibition leads to a decrease in downstream signaling, including decreased activation of the mitogen-activated protein kinases and p38 MAPK pathways. BMS-833923 has also been shown to be active against metastatic pancreatic cancer cells. Pharmacokinetic studies have shown that BMS-833923 is metabolized via CYP3A4/5; however, this does not affect its antitumor activity or toxicity.</p>Formula:C30H27N5OPurity:Min. 95%Molecular weight:473.58 g/mol
